Background and Purpose-The diagnosis of transient ischemic attack is challenging. Evidence of acute ischemia on MRI diffusion-weighted imaging is highly variable and confirmed in only about one-third of patients. This study investigated the significance of blood-brain barrier dysfunction (BBBD) mapping in patients with transient neurological deficits, as a diagnostic and prognostic biomarker required for risk stratification and stroke prevention. Methods-We used dynamic contrast-enhanced MRI to quantitatively map BBBD in a prospective cohort study of 57 patients diagnosed with transient ischemic attack/minor stroke and 50 healthy controls. Results-Brain volume with BBBD was significantly higher in patients compared with controls (P=0.002). BBBD localization corresponded with the clinical presentation in 41 patients (72%) and was more extensive in patients with acute infarct on diffusion-weighted imaging (P=0.05). Patients who developed new stroke during follow-up had a significantly greater BBBD at the initial presentation (P=0.03) with a risk ratio of 5.35 for recurrent stroke. Conclusions-This is the first description of the extent and localization of BBBD in patients with transient ischemic attack/ minor stroke. We propose BBBD mapping as a valuable tool for detection of subtle brain ischemia and a promising predictive biomarker required for risk stratification and stroke prevention.
M
inor ischemic stroke and transient ischemic attack (TIA) are brief episodes of neurological deficits commonly distinguished by the presence of acute brain infarction on diffusion-weighted magnetic resonance imaging (MRI; DWI). 1 Positive DWI is associated with an imminent risk of debilitating stroke and mortality. 2 Nevertheless, the diagnosis of TIA remains challenging and TIA mimics comprise nearly 60% of clinic referrals. 3 The unmet need for a reliable diagnostic biomarker of microvascular brain disease is affirmed by TIA cohort studies displaying high variance of 9% to 67% in the frequency of DWI positivity. 4 Blood-brain barrier dysfunction (BBBD), a prominent feature of the injured brain, has been suggested as a diagnostic and therapeutic target in cerebral ischemia. 5 Yet, no clinical studies have characterized microvascular pathology after TIA/minor stroke and its relation to ischemic brain disease. We developed and validated an MRI-based method for quantitative evaluation of brain vascular permeability. 6 Here we describe the characteristics and extent of BBBD in patients presenting with transient neurological deficits in comparison to healthy controls.
Methods

Design
We conducted a prospective cohort study in a tertiary stroke referral center in southern Israel, serving a population of >1.2 million, from October 2012 through December 2016. Inclusion criteria were age >18 years, presentation with transient neurological deficits attributed to brain ischemia, and diagnosis of TIA or minor stroke by a stroke specialist. We excluded patients with contraindications to MRI, alternative diagnosis to explain transient deficits and nonresolving symptoms during emergency department care. Baseline characteristics and clinical data were obtained from electronic medical record database. Data included duration of symptoms and hospital stay, comorbidities, critical vessel stenosis, laboratory data, recurrent stroke/TIA, and new neurological diagnoses during the follow-up period, until October 31, 2017. All subjects underwent brain MRI. To determine normal BBB permeability values, brain scans were acquired from 50 healthy volunteers with no history of brain disorders, including 23 age-matched controls. The study was approved by Soroka Medical Center Ethics Committee. A written informed consent was obtained from all participants. The data that support the findings of this study are available from the corresponding author on reasonable request.
Imaging
All subjects were imaged on a 3T Philips Ingenia MRI. For details of image acquisition see the online-only Data Supplement. Briefly, T1-and T2-weighted imaging, FLAIR, diffusion, and SWI data were acquired, followed by dynamic contrast-enhanced sequence. After 5 dynamic scans, the contrast agent gadoterate meglumine (Gd-DOTA, Dotarem, Guerbet, France, 0.1 mmol/kg, 0.5M, 1.5 mL/s) was administered intravenously. Experienced neuroradiologists evaluated each DWI map for evidence of acute infarction, defined as a hyperintense lesion with corresponding ADC hypointensity.
Permeability Quantification
By applying a linear fit during the late (6-17 minutes) phase of acquired dynamic contrast-enhanced data, the rate of contrast agent accumulation was calculated in each brain voxel, to reflect microvascular permeability 6 ( Figure 1A ; Material in the online-only Data Supplement). Permeability values were considered pathological (ie, BBBD) when exceeding the 95th percentile of the corresponding mean cumulative distribution function from healthy controls. Voxels with BBBD were color-coded and superimposed on the anatomic scans ( Figure 1A through 1D ). Quantitative analysis of the percent of voxels with BBBD was performed for the entire brain, white matter, gray matter, and 18 nonoverlapping brain regions (Figure 2A through 2C).
Statistics
Data analysis was performed using SPSS 24.0 (SPSS Inc, Chicago, IL). Student t test, Mann-Whitney U, Kruskal-Wallis, Wilcoxon signed-rank test, χ 2 , or Fisher exact test were used for comparisons. Risk ratios with 95% CIs were calculated. Statistical significance was determined as P≤0.05.
Results
In total, 107 subjects were included. Mean patients' age was 58.4 years (n=57, range, 36-84 years; 64.9% men). All patients had low modified Rankin Scale score (≤2) and low National Institutes of Health Stroke Scale score (≤5). The mean time from emergency department presentation to MRI scan was 3.1±2.1 days. For the majority of patients (n=39, 68%), the time between symptom onset and MRI scan was <72 hours, 15 patients (26%) were scanned between 72 hours and 7 days, and 3 patients (5%) were scanned during the subacute phase (≥7 days). The median follow-up duration was 1.7 years (range, 1.1-4.9 years). Mean age of the 50 healthy volunteers was 40.7 years (range, 24-85 years; 65.3% men), including 23 agematched controls (mean 55.8 years, range, 37-85 years).
BBBD was not detected in 4/57 patients (7%; Figure 1B ). Most patients (n=42, 73.6%) had a focal leakage ( Figure 1D ), whereas some displayed diffuse pathology, extending over > three lobes (n=11, 19.2%). Quantification of the percentage of voxels with BBBD revealed significant leakage in patients compared with controls (P=0.002). Since BBBD has been 
Stroke
May 2019
reported in aging, 7 we compared patients with either young (n=27; age range, 24-32 years; mean age, 27.9) or agematched (n=23; age range, 37-85.1; mean, 55.8) controls. Brain volume with BBBD was significantly higher in patients compared with both young (P=0.001) and age-matched controls (P=0.05; Figure 2A ). Regional analysis revealed a higher percent of voxels with BBBD in the white matter (P=0.02) but not in gray matter of patients compared with age-matched controls (P=0.07; Figure 2B) . Similarly, leakage analysis in distinct brain regions showed greater BBBD in 12 cortical and sub-cortical areas, namely bilateral frontal, parietal, temporal, cerebellar, thalamic, and deep nuclei regions (P<0.05; Figure 2C ).
Comparison of the extent of BBBD in patients diagnosed with minor stroke (DWI-positive scan, n=26, 45.6%) or TIA (DWI-negative, n=31, 54.4%), revealed a significantly higher brain volume with BBBD in patients with minor stroke (P=0.05; Figure 3A ). This was true for both white matter (P=0.05) and gray matter (P=0.02) leakage. Comparison of the brain volume with BBBD in patients scanned after complete symptom resolution (n=49, 86%) and symptomatic patients at the time of the scan (n=8), showed no statistical significance. Crossing BBBD maps with the documented clinical presentation revealed that BBBD localization was consistent with at least 1 sign/symptom in 41 patients (72%), of whom 21/26 (80.8%) had positive DWI and 20/31 (64.5%) had negative DWI. Patients presenting with language deficits were more likely to display a localizing BBBD (P=0.015, 20/22, 90.9%; 10 of whom had positive DWI) than patients presenting with other neurological deficits (21/35, 60%). The anatomic localization of DWI lesions was consistent with the clinical presentation in most minor stroke patients (23/26, 88.5%). No signs or symptoms at presentation were significantly correlated with either positive or negative DWI findings. Patients with positive DWI had a higher prevalence of atrial fibrillation (P=0.014). No differences between the 2 groups were found in other clinical variables (Table I in the online-only Data Supplement).
BBBD association with ischemia and the reported increased risk for delayed stroke in patients with positive-DWI, 2 raised the hypothesis that patients with BBBD would be more likely to develop recurrent ischemic events. In our cohort, 7 patients were diagnosed with new stroke during the follow-up period (Table I in the online-only Data Supplement). Although the occurrence of a new stroke was uncorrelated to the initial DWI findings (P>0.99), patients who later developed a stroke were found to have higher brain volume with BBBD at their earlier presentation with transient deficits (P=0.03; Figure 3B ). Furthermore, patients with extensive BBBD (≥interquartile range above the median of pathological voxels) had a risk ratio of 5.35 (95% CI=1.50-19.09) for delayed stroke, compared with a risk ratio of 0.89 (95% CI, 0.22-3.63) for patients with positive DWI. Patients who developed a new stroke had a higher modified Rankin scale at the initial presentation with transient deficits (P=0.03), and 6/7 patients had reported transient symptoms before their first TIA/minor stroke (P=0.008). No differences were found between the 2 groups in other clinical characteristics (Table I in the online-only Data Supplement). Risk of delayed stroke for patients with ABCD 2 score ≥4 was insignificant (risk ratio=1.03; 95% CI, 0.25-4.18). Figure 3C shows DWI and BBBD maps of a 68-year-old patient who presented with a brief episode of slurred speech and right arm weakness. Initial MRI showed a small left parietal DWI lesion surrounded by BBBD. Two weeks later, he developed a new ischemic stroke at the area previously showing BBBD.
Discussion
This is the first report on quantitative evaluation of BBB integrity in patients with transient neurological deficits and its association with clinical presentation and outcome. We found BBBD in brain areas corresponding to the clinical presentation in most patients, including 64.5% of patients with a negative DWI. Language deficits at presentation were highly suggestive for localizing BBBD. This could be explained by the combination of high prevalence of ischemic stroke in the middle cerebral artery territory, the high vulnerability to hypoperfusion of language-processing areas, 8 and interregional differences in BBB susceptibility to injury. 9 The significant leakage in patients with ischemic lesions on DWI, supports the notion that BBBD reflects an underlying microvascular pathology. Observing BBBD during acute or subacute phases as well as after symptom resolution, highlights the role of dynamic contrast-enhanced -MRI in the diagnosis of cerebrovascular disease. Sustained BBBD could signify a subtle transient ischemia that was not sufficient to alter the DWI signal, and a long-lasting microvascular injury that underlies transient neurological dysfunction. Since timely initiation of stroke prevention strategies may reduce the total stroke burden, the association of BBBD with development of recurrent brain infarct suggests a potential role for BBBD mapping in identifying patients at risk of stroke.
We propose a clinically-applicable quantitative approach for the diagnosis of microvascular pathology and subtle brain ischemia. Large-scale studies are required to confirm the diagnostic, prognostic, and predictive value of quantitative BBB mapping. 
